WallStreetZenWallStreetZen

NASDAQ: OTLK
Outlook Therapeutics Inc Stock Ownership - Who owns Outlook Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Outlook Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Ghiath M. SukhtianDirector2025-05-274,285,714$1.40
$6.00MBuy
Ghiath M. SukhtianDirector2025-01-173,458,571$2.51
$8.68MBuy
Lawrence A. KenyonChief Financial Officer2024-09-265,000$5.69
$28.45kBuy

1 of 1

OTLK insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when OTLK insiders and whales buy or sell their stock.

OTLK Shareholders

What type of owners hold Outlook Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Ghiath M. Sukhtian249.05%83,599,563$152.15MInsider
Faisal Ghiath Sukhtian166.48%55,884,786$101.71MInsider
Biolexis Pte Ltd75.80%25,443,159$46.31MInsider
Arun Kumar Pillai68.47%22,982,529$41.83MInsider
Pankaj Mohan24.68%8,285,115$15.08MInsider
Syntone Ventures LLC5.08%1,705,438$3.10MInsider
Schonfeld Strategic Advisors LLC4.63%1,552,744$2.83MInstitution
Blackrock Inc3.70%1,242,372$2.26MInstitution
Sphera Funds Management Ltd2.55%857,142$1.56MInstitution
Vanguard Group Inc2.49%837,407$1.52MInstitution

1 of 3

OTLK vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
OTLK3.41%96.59%Net BuyingNet Buying
CRVO3.23%96.77%Net BuyingNet Buying
ACET67.53%19.44%Net Selling
ANL0.05%0.00%
CLSD11.34%35.27%Net Buying
View Top Biotech Stocks

Outlook Therapeutics Stock Ownership FAQ

Who owns Outlook Therapeutics?

Outlook Therapeutics (NASDAQ: OTLK) is owned by 21.11% institutional shareholders, 598.25% Outlook Therapeutics insiders, and 0.00% retail investors. Ghiath M. Sukhtian is the largest individual Outlook Therapeutics shareholder, owning 83.60M shares representing 249.05% of the company. Ghiath M. Sukhtian's Outlook Therapeutics shares are currently valued at $152.15M.

If you're new to stock investing, here's how to buy Outlook Therapeutics stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.